All In Biotech

Drug Trial Radar · NCT05985694

AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

A Single-blind (Patient-blind), Randomized, Placebo-controlled, Intranasal Administration Study on Mechanisms and Potential Efficacy of AD17002 in Subjects With Poorly Controlled, Moderate to Severe Eosinophilic Asthma

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Nov 27, 2023

Primary completion

Jan 28, 2025

Study completion Apr 27, 2025

Sponsor

Lead sponsor
Advagene Biopharma Co. Ltd.Industry
Sponsor type
Industry
Collaborators
Taipei Medical University Hospital
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1. Could the AD17002 intranasal immunomodulator improve the clinical condition of eosinophilic asthmatic patients? 2. Could patients self-administer AD17002 via the intranasal route? 3. Is the AD17002 at multiple doses safe for asthmatic patients? 4. Participants will be asked to self-administer two doses per week for a total of 6 weeks (11 doses). A diary on AD17002 usage, adverse events, and reliever medication will be recorded.

Conditions

  • Eosinophilic Asthma

Interventions

  • AD17002Drug

    The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.

  • PlaceboDrug

    Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1 improvementTime frame: Day 1 to Day 78

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Medical University Hospital

    Taipei, Taiwan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.